Khwaja Tariq
Psychiatry · Friendswood, TXNPI 1639466717
Payments from drug & device makers
Across 438 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$841
- AbbVie$750
- Alkermes, Inc.$512
- Teva Pharmaceuticals USA, Inc.$481
- Takeda Pharmaceuticals U.S.A., Inc.$423
- plus $4K from 23 others
What the payments were for
- Food & beverage$8,118100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 74 | $1,406 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $841 |
| AbbVie(2 entities) | 49 | $750 |
| Alkermes, Inc. | 26 | $512 |
| Teva Pharmaceuticals USA, Inc. | 24 | $481 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $423 |
| Almatica Pharma LLC | 25 | $412 |
| Axsome Therapeutics, Inc. | 16 | $379 |
| Corium, LLC | 26 | $375 |
| Otsuka America Pharmaceutical, Inc. | 20 | $370 |
| Neurocrine Biosciences, Inc. | 12 | $336 |
| Supernus Pharmaceuticals, Inc. | 20 | $291 |
| Lundbeck LLC | 12 | $261 |
| E.r. Squibb & Sons, L.L.C. | 13 | $261 |
| Vanda Pharmaceuticals Inc. | 9 | $168 |
| Tempus AI, Inc | 7 | $143 |
| Indivior Inc. | 6 | $123 |
| Tris Pharma Inc | 6 | $122 |
| Biogen | 3 | $83 |
| Sunovion Pharmaceuticals Inc. | 4 | $67 |
| Ironshore Pharmaceuticals Inc. | 3 | $60 |
| Idorsia Pharmaceuticals US Inc | 3 | $57 |
| Neuronetics, Inc. | 2 | $46 |
| Noven Therapeutics, LLC | 2 | $42 |
| Shire North American Group Inc | 2 | $31 |
| Neos Therapeutics, LP | 2 | $28 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Eisai Inc. | 1 | $13 |
How this compares
$8,118 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 39 | $341,648 |
| SpravatoEsketamine Hcl | 99 | $208,557 |
| VraylarCariprazine Hcl | 87 | $132,601 |
| AustedoDeutetrabenazine | 15 | $107,549 |
| Invega SustennaPaliperidone Palmitate | 25 | $72,386 |
| TrintellixVortioxetine Hydrobromide | 70 | $49,672 |
| RexultiBrexpiprazole | 26 | $47,238 |
| AristadaAripiprazole Lauroxil | 14 | $46,271 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $30,772 |
| AuvelityDextromethorphan Hbr/Bupropion | 23 | $27,875 |
| EmsamSelegiline | 11 | $27,214 |
| BelsomraSuvorexant | 58 | $24,691 |
| Lisdexamfetamine Dimesylate | 60 | $11,583 |
| Lurasidone Hcl | 24 | $5,656 |
| QuviviqDaridorexant Hcl | 11 | $5,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $336 | $341,64839 claims |
| Johnson & JohnsonSpravato, Invega Sustenna | $1,406 | $280,944124 claims |
| AbbVieVraylar | $750 | $132,60187 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $481 | $107,54915 claims |
| Alkermes, Inc.Aristada, Lybalvi | $512 | $77,04331 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $423 | $49,67270 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $370 | $47,23826 claims |
| Axsome Therapeutics, Inc.Auvelity | $379 | $27,87523 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $57 | $5,37911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Friendswood
- Napoleon HigginsFriendswood$1.1M
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.